HUMA Humacyte Inc
Company Analysis
Latest News
🟢 Humacyte is trading 7.27% up in pre-market after positive Phase 3 dialysis results
Humacyte is trading 7.27% up now at $0.59 after investors weighed positive Phase 3 dialysis results and plans to file a supplemental biologics license...
🟢 Humacyte is trading 10.89% up in after-hours trading despite no new company-specific catalyst
Humacyte is trading at $0.61, up 10.89% in after-hours trading, with no new company-specific catalyst identified in available coverage. - Shares declined...
🟢 Humacyte is trading 6.65% up in after-hours trading after positive Phase 3 dialysis data
Humacyte is trading 6.65% up in after-hours trading at $0.59 after releasing second-quarter results and highlighting positive Phase 3 dialysis data. -...
🔴 Humacyte is trading 10.9% down today after missing Q2 revenue and EPS estimates
Humacyte is trading 10.9% down at $0.59 after its August 12, 2026, second-quarter results missed analyst expectations. - EPS was -$0.16 versus -$0.09...
🔴 Humacyte is trading 5% down today after Q2 revenue and EPS missed estimates
Humacyte is trading 5.17% down at $0.63 after its August 12, 2026, second-quarter earnings release showed revenue and EPS misses. - Revenue was $410,000...
🔴 Humacyte is trading 12.68% down today after Q2 results missed estimates
Humacyte is trading 12.68% down now at $0.62 after its August 12, 2026 second-quarter results missed consensus expectations. - Revenue was $410,000 versus...
🔴 Humacyte is trading 9.92% down today after Q2 revenue and EPS missed expectations
Humacyte is trading 9.92% down at $0.64 after second-quarter revenue and EPS missed expectations. - Revenue was $0.41 million versus approximately $1.14...
Humacyte's second quarter 2026 revenue reached $0.4M as dialysis study results support sBLA filing
Humacyte reported a transformative second quarter 2026, headlined by positive Phase 3 results for its dialysis pipeline and the initial commercial traction of...
Humacyte Drops 10% Before Earnings — Can a Biotech Running Low on Cash and Trading Below $1 Convince Investors Its Science Is Worth the Wait?
Shares of Humacyte sank 10.2% to $0.64 ahead of the company's Q2 2026 earnings release, scheduled for 8:00 a.m. Eastern today. The sell-off, against a modestly...
🔴 Humacyte Trades Down 10.15% in Pre-Market Following Q2 Revenue Miss and Higher-Than-Expected Loss
Humacyte is trading at $0.64 (-10.15%) in pre-market as investors react to its August 12, 2026, second-quarter results. • The company reported Q2 product...
🔴 Humacyte is trading 7.4% down in pre-market before August 12 Q2 2026 results
Humacyte is trading 7.4% down at $0.66 ahead of its scheduled second-quarter 2026 results. - Results and a business update are scheduled for 8:00 a.m. Eastern...
Humacyte Inc Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
Humacyte is expected to report a second-quarter 2026 net loss of $0.10 per share on revenue of $1.12 million, with the stock currently trading at approximately...
🔴 Humacyte is trading 5% down today
Humacyte is trading at $0.69, down -5.04%, with no clear catalyst identified. - No August 6, 2026 company-specific announcement was found in Humacyte’s...
🟢 Humacyte is trading 6% up today amid improving broader market sentiment
Humacyte is trading 6% up at $0.69 today, appearing to move in tandem with a broader market rally rather than any stock-specific developments. • Major indices...
🟢 Humacyte is trading 5% up today amid BTIG Buy Rating and continued FDA momentum
Humacyte is trading up 5% at $0.66. The stock is receiving a boost after BTIG Research issued a Buy Rating today, July 30. This also reflects continued...
🟢 Humacyte is trading 6.2% up today, bouncing after profit-taking following FDA trial clearance rally
Humacyte is trading at $0.67 (6.2% up) in pre-market, bouncing back after yesterday’s profit-taking drop that followed its FDA Investigational New Drug...
🔴 Humacyte is trading 6.1% down today on profit-taking after FDA trial clearance spike
Humacyte is trading 6.1% down at $0.63 as investors lock in gains following a sharp rally triggered by the FDA's clearance of its Investigational New Drug...
Humacyte Wins FDA Clearance for Bioengineered Heart Bypass Vessel Trial
Humacyte, Inc. received FDA clearance for its Investigational New Drug (IND) application to study the coronary tissue engineered vessel (CTEV). The company...
🟢 Humacyte rises 6.0% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🟢 Humacyte is trading 7.2% up today amid broader risk-on market sentiment
Humacyte is trading 7.2% up at $0.67 in pre-market, rebounding from recent weakness and trading in the low-$0.60s. • The move appears aligned with a broader...